Profilo
Rob Ortmann worked as an Executive Director of Clinical Development at Horizon Therapeutics Plc from 2021 to 2022.
Prior to that, he worked as the Head of US Immunology at AstraZeneca PLC.
He holds a doctorate degree from Case Western Reserve University School of Medicine.
Precedenti posizioni note di Rob Ortmann
| Società | Posizione | Fine |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Direttore Tecnico/Scientifico/R&S | 01/05/2022 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Formazione di Rob Ortmann
| Case Western Reserve University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Aziende private | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Rob Ortmann
